Our Pricing

Highest Dose Wegovy vs Mounjaro: UK Comparison Guide

When comparing the highest dose Wegovy vs Mounjaro, patients often want to understand which maximum-strength weight loss injection delivers superior results. Wegovy's highest dose is 2.4mg semaglutide weekly, whilst Mounjaro's maximum maintenance dose is 15mg tirzepatide weekly. Both are GLP-1 receptor agonists licensed by the MHRA for chronic weight management in adults with obesity or overweight with weight-related comorbidities, but they differ significantly in mechanism, efficacy data, and tolerability profiles.

What Are the Highest Dose Wegovy vs Mounjaro Formulations?

The highest dose Wegovy vs Mounjaro comparison centres on two distinct GLP-1-based therapies at their maximum licensed strengths. Wegovy (semaglutide) reaches a maintenance dose of 2.4mg administered subcutaneously once weekly, typically after a 16-week dose escalation starting from 0.25mg [1]. This gradual titration minimises gastrointestinal side effects whilst allowing patients to adapt to the medication's appetite-suppressing effects.

Mounjaro (tirzepatide) offers a highest dose of 15mg once weekly, though many patients achieve their weight loss goals on the 10mg or 12.5mg doses [2]. Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. This dual mechanism distinguishes Mounjaro from Wegovy's single GLP-1 action, potentially explaining differences in weight loss magnitude observed in head-to-head trials.

Both medications require subcutaneous injection using pre-filled pens, with dose escalation protocols designed by the manufacturers to optimise tolerability. Patients typically start Wegovy at 0.25mg weekly for four weeks, then increase every four weeks through 0.5mg, 1mg, 1.7mg, before reaching the 2.4mg maintenance dose. Mounjaro begins at 2.5mg weekly, increasing every four weeks through 5mg, 7.5mg, 10mg, 12.5mg, to the optional 15mg maximum dose. All dose changes require clinical review and prescriber approval.

Highest Dose Wegovy vs Mounjaro: Clinical Trial Efficacy Data

When evaluating the highest dose Wegovy vs Mounjaro for weight loss efficacy, the STEP and SURPASS trial programmes provide robust comparative data. In the STEP 1 trial, participants taking Wegovy 2.4mg achieved an average weight loss of 14.9% of baseline body weight over 68 weeks, compared to 2.4% with placebo [1]. Approximately 50% of patients on the highest dose Wegovy lost at least 15% of their starting weight, whilst 32% achieved ≥20% weight reduction.

The SURPASS-2 head-to-head trial directly compared tirzepatide against semaglutide 1mg (not the 2.4mg Wegovy dose, but the diabetes-licensed strength). Participants on the highest dose Mounjaro (15mg tirzepatide) lost an average of 15.0kg compared to 5.7kg with semaglutide 1mg over 40 weeks [2]. Subsequent analysis of the SURMOUNT-1 trial showed that Mounjaro 15mg delivered average weight loss of 20.9% at 72 weeks in participants without diabetes, representing superior outcomes compared to historical Wegovy data [3].

It is important to note that no published trial has directly compared the highest dose Wegovy vs Mounjaro (2.4mg semaglutide vs 15mg tirzepatide) in the same study population. Indirect comparisons suggest Mounjaro's dual-agonist mechanism may confer a modest weight loss advantage of approximately 3-5 percentage points, though individual responses vary considerably based on adherence, lifestyle modifications, and metabolic factors. Both medications demonstrate clinically meaningful weight reduction when combined with reduced-calorie diet and increased physical activity.

Weight Loss Outcomes by Dose Strength

Across the dose range, both medications show dose-dependent weight loss, with the highest dose Wegovy vs Mounjaro formulations delivering maximum efficacy. For Wegovy, the 2.4mg dose consistently outperformed lower strengths in the STEP trials, with the 1.7mg dose achieving approximately 13.8% weight loss versus 14.9% at 2.4mg [1]. For Mounjaro, the 15mg dose produced 20.9% average weight loss compared to 19.5% at 10mg and 15.0% at 5mg in SURMOUNT-1 [3]. These data support escalating to the highest tolerated dose for optimal weight management outcomes, subject to prescriber assessment and individual tolerability.

Side Effects Profile: Highest Dose Wegovy vs Mounjaro Comparison

The side effect profile of the highest dose Wegovy vs Mounjaro requires careful consideration, as gastrointestinal adverse events are dose-dependent for both medications. With Wegovy 2.4mg, the most commonly reported side effects include nausea (44% of participants), diarrhoea (30%), vomiting (24%), and constipation (24%) in the STEP trials [1]. Most gastrointestinal symptoms were mild to moderate in severity and diminished over time, particularly when dose escalation protocols were followed correctly.

Mounjaro 15mg demonstrated a similar gastrointestinal side effect profile, with nausea reported in approximately 33% of participants, diarrhoea in 23%, and vomiting in 15% during the SURPASS trials [2]. Interestingly, despite being the highest dose, tirzepatide's dual-agonist mechanism may modulate gastric emptying differently than pure GLP-1 agonists, potentially explaining why some patients report better tolerability with Mounjaro compared to Wegovy, whilst others experience the opposite.

Both medications carry important safety considerations beyond gastrointestinal effects. Rare but serious risks include pancreatitis, gallbladder disease, acute kidney injury (usually secondary to dehydration from vomiting/diarrhoea), and hypoglycaemia when used with insulin or sulfonylureas. There is a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though human relevance remains unclear. Patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use either medication. All prescription decisions require individualised risk-benefit assessment by a UK prescriber.

Managing Side Effects at Maximum Doses

When using the highest dose Wegovy vs Mounjaro formulations, proactive side effect management improves treatment adherence and outcomes. Our clinical team at Cured Pharmacy advises patients to eat smaller, more frequent meals, avoid high-fat foods that delay gastric emptying, and maintain adequate hydration throughout treatment. If nausea persists, remaining on a lower dose (such as Wegovy 1.7mg or Mounjaro 10mg) for an additional month before escalating can improve tolerability whilst still delivering substantial weight loss. Never adjust dosing without prescriber guidance, as abrupt changes may worsen gastrointestinal symptoms or reduce efficacy.

Cost Analysis: Highest Dose Wegovy vs Mounjaro UK Pricing

Understanding the cost difference between the highest dose Wegovy vs Mounjaro helps patients make informed decisions about long-term weight management therapy. At Cured Pharmacy, Mounjaro is available from £124.99 per four-week supply, subject to clinical assessment and prescriber approval. This represents the cheapest UK price for genuine, MHRA-licensed tirzepatide, with transparent upfront pricing before consultation. New patients can Save £20 off their first order using code Weightlossnew, reducing the initial cost to £124.99.

Wegovy pricing at Cured Pharmacy starts from £124.99 per four-week supply, making it a more economical option for patients who achieve satisfactory weight loss on semaglutide alone. The price difference reflects the medications' different manufacturing processes, licensing timelines, and market positioning. However, cost-effectiveness should be evaluated alongside efficacy—if Mounjaro's superior weight loss results (based on trial data) allow a patient to reach their goal weight faster or with better maintenance, the higher upfront cost may represent better long-term value.

Neither medication is routinely available on NHS prescription for weight management outside specialist obesity services, meaning most UK patients access these treatments privately. At Cured Pharmacy, we guarantee the lowest UK prices for both the highest dose Wegovy vs Mounjaro formulations, with no hidden fees, free online consultation under three minutes, and discreet next-day delivery. All pricing includes clinical assessment by our UK-registered prescribers, ongoing support from superintendent pharmacist Tarun Kumar (GPhC 2233073), and genuine medicines sourced through licensed UK wholesalers.

Which Is Better: Highest Dose Wegovy vs Mounjaro for Weight Loss?

Determining which is superior between the highest dose Wegovy vs Mounjaro depends on individual patient factors rather than a universal answer. Clinical trial data suggests Mounjaro 15mg delivers approximately 3-6 percentage points greater average weight loss compared to Wegovy 2.4mg when comparing across studies (20.9% vs 14.9% at similar timepoints) [1][3]. However, these are population averages—individual responses vary significantly based on baseline BMI, metabolic health, adherence, dietary changes, and genetic factors affecting GLP-1 receptor sensitivity.

For patients who prioritise maximum weight loss potential and can tolerate the higher cost, the highest dose Mounjaro represents the most efficacious option currently available in the UK based on published trial data. Conversely, patients who achieve their weight loss goals on Wegovy 2.4mg may find the lower cost and established safety profile (semaglutide has been used for diabetes since 2017, versus tirzepatide's 2022 approval) make it the preferable choice. Some patients also report subjective differences in appetite suppression, energy levels, and gastrointestinal tolerability between the two medications, which can only be determined through supervised trial.

Our clinical approach at Cured Pharmacy involves individualised assessment of each patient's weight loss history, comorbidities, budget, and treatment preferences. Superintendent pharmacist Tarun Kumar and our UK-registered prescribing team evaluate whether the highest dose Wegovy vs Mounjaro is appropriate for each individual, or whether starting on a lower dose, alternative GLP-1 therapy, or non-injectable option better suits their needs. All treatment decisions require ongoing monitoring, with dose adjustments based on efficacy, tolerability, and clinical response over time.

Patient Selection Criteria for Maximum Doses

Not all patients require or benefit from the highest dose Wegovy vs Mounjaro formulations. NICE guidance recommends GLP-1 receptor agonists for weight management in adults with BMI ≥35 kg/m² (or ≥32.5 kg/m² in certain ethnic groups) or BMI ≥30 kg/m² with weight-related comorbidities such as type 2 diabetes, hypertension, or obstructive sleep apnoea [4]. Patients should demonstrate commitment to lifestyle modification, have no contraindications (pregnancy, breastfeeding, personal/family history of medullary thyroid cancer, severe gastrointestinal disease), and be able to attend regular clinical reviews. Escalation to maximum doses is reserved for those who tolerate lower strengths well and require additional weight loss to reach clinical targets.

How to Access the Highest Dose Wegovy vs Mounjaro at Cured Pharmacy

Accessing the highest dose Wegovy vs Mounjaro through Cured Pharmacy follows a safe, regulated process compliant with MHRA and GPhC standards. All prescription weight loss medications require clinical assessment by a UK-registered prescriber before dispensing. Our online consultation takes under three minutes, covering your medical history, current medications, weight loss goals, and any contraindications to GLP-1 therapy. This ensures the prescribed treatment is clinically appropriate and safe for your individual circumstances.

Once your consultation is reviewed and approved by our prescribing team, your medication is dispensed by our GPhC-registered pharmacy (registration number 9012511) and dispatched via next-day delivery in 100% discreet packaging. We source only genuine, UK-licensed Wegovy and Mounjaro from authorised wholesalers—never grey-market imports or counterfeit products. Patients receive full dosing instructions, injection technique guidance, and ongoing support from our clinical team throughout their weight loss journey.

For patients comparing the highest dose Wegovy vs Mounjaro options, our prescribers can discuss which medication aligns best with your clinical profile, budget, and weight loss targets during the consultation. We offer transparent upfront pricing (£124.99 for Mounjaro, £124.99 for Wegovy) with no hidden fees, and new patients Save £20 using code Weightlossnew on their first order. Follow-up prescriptions are managed through your online account, with regular clinical reviews to monitor progress, adjust doses as needed, and ensure safe, effective long-term weight management. To begin your assessment, visit our weight loss consultation page or contact our team on (+44) 116 4646009.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. [accessed 15 August 2026]
2. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., Brown, K. D., SURPASS-2 Investigators. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. [accessed 15 August 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. [accessed 15 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.